This week
The Melanotan self-injection photos went viral on June 4th — and the approved version barely made a sound
A self-injection before-and-after showing five months of Melanotan-II use circulated across Reddit and X this week, generating millions of impressions and the usual split: half the comments alarmed at the severity of the pigmentation change, the other half asking where to find it. [The coverage on June 4, 2026](https://www.boredpanda.com/man-reveals-results-after-injecting-himself-melanotan-2/) collected expert commentary from dermatologists who confirmed the darkening was within the documented range of Melanotan-II effects — and who noted that without FDA approval, the dosing, contaminants, and long-term health outcomes of any particular batch remain genuinely unknown. What neither the viral post nor most of the commentary addressed is that a peptide from the same melanocortin family — afamelanotide, sold as Scenesse — already has FDA approval, a completed Phase 3 trial program, and a real medical use. In April 2026, the FDA quietly [relaxed the SCENESSE postmarketing requirement](https://www.clinuvel.com/2026/04/fda-relaxes-scenesse-postmarketing-requirement-20260427/) by eliminating a mandated cardiac study — the agency concluded that routine safety monitoring was sufficient. That development landed without the viral attention the self-injection photos generated six weeks later.
The actual biology
Five melanocortin receptors do five different things — and which one you hit matters enormously
The melanocortin system comprises five receptor subtypes — MC1R through MC5R — each with distinct expression patterns and functional roles. MC1R is the primary controller of skin pigmentation: it sits on melanocytes, where activation by alpha-melanocyte-stimulating hormone or synthetic agonists triggers eumelanin synthesis and produces the darker pigmentation response. MC4R is centrally expressed in the hypothalamus and brainstem, where it regulates energy balance, appetite, and aspects of cardiovascular and sexual function. MC2R mediates adrenocortical stress responses. MC3R has roles in energy homeostasis and peripheral metabolic signaling. MC5R is expressed in exocrine glands. Afamelanotide is a synthetic alpha-MSH analog designed to preferentially activate MC1R with an extended half-life compared to the native hormone. That selective targeting was the clinical logic for its development: patients with erythropoietic protoporphyria cannot tolerate sunlight because heme precursors accumulate in their skin and cause a severe phototoxic reaction. Driving MC1R-mediated eumelanin production provides a physical light-blocking effect that reduces that reaction. Melanotan-II works differently — it is a cyclic analog with substantially lower receptor selectivity, hitting MC1R, MC3R, MC4R, and MC5R in the same injection. That receptor promiscuity is not a side effect of contamination; it is the pharmacological profile of the molecule. The [PubMed literature on afamelanotide](https://pubmed.ncbi.nlm.nih.gov/?term=afamelanotide) documents both the selectivity data and the clinical program.
What the internet says
The tanning claim travels because MC1R activation really does change pigmentation — it is just not the whole story
The tanning claim for Melanotan-II travels because the underlying biology is real: MC1R activation does produce increased melanin in skin cells. People who use the compound get darker. For users with fair skin and limited natural tanning capacity, the change can be dramatic and fast — which is why the before-and-after format keeps working as content. The claim is not fabricated, but the frame is incomplete. The same injection that activates MC1R also activates MC4R in the central nervous system. That MC4R activity is why documented side effects of Melanotan-II in the pharmacological literature include nausea, flushing, and spontaneous erection — not because something went wrong with the batch, but because those are the known consequences of hitting MC4R signaling pathways in the hypothalamus and spinal cord. Wellness content around Melanotan-II consistently presents this as a manageable inconvenience or a sign that the compound is working, rather than as a consequence of hitting a receptor whose central role in metabolic and cardiovascular regulation has nothing to do with the tanning goal. The approved drug, afamelanotide, was engineered specifically to retain MC1R activity while reducing the off-target receptor engagement that produces that side-effect profile.
What the data shows
Afamelanotide has Phase 3 trial data and an FDA label — Melanotan-II has forum logs and a melanoma case report
Afamelanotide clinical record is narrow and specific. Phase 3 trials demonstrated that subcutaneous afamelanotide implants reduced the number of phototoxic reaction hours in EPP patients compared to placebo; those results supported FDA approval in October 2019. The current Phase 3 vitiligo trial (CUV105) has enrolled more than 200 patients across 37 sites globally, with topline results expected in the second half of 2026 — an expansion of the evidence base in progress, not a current approval. [The DailyMed afamelanotide label entry](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=afamelanotide) documents the approved indication, the administration route — a bioresorbable implant placed by a healthcare provider, not a self-injection product — and the monitored patient population. The evidence trail for Melanotan-II runs through different channels. A case report published in Oral Oncology in 2025 documented [Melanotan-II nasal spray as a potential risk factor for oral mucosal malignant melanoma](https://www.sciencedirect.com/science/article/abs/pii/S0901502725001109), adding to a series of case reports linking unsupervised use to abnormal mole changes and melanoma concerns. No completed randomized controlled trial evaluates the tanning application. The compound is not registered on the FDA compounding review docket in the same way BPC-157, TB-500, or even KPV have been this year.
Approved — PeptideFactCheck stance
The approval tier marks exactly what happened: a specific use was reviewed, proved, and labeled
Afamelanotide holds the Approved evidence tier on PeptideFactCheck. The tier meaning — regulatory certainty for labeled uses, not a blank check for every claim — applies precisely here. The labeled use is narrow: erythropoietic protoporphyria in adults, administered by a healthcare provider using a bioresorbable subcutaneous implant on a monitored clinical schedule. That is the evidence-backed, FDA-reviewed application. It is not a cosmetic tanning protocol, not an off-the-internet self-injection compound, and not interchangeable with Melanotan-II because both contain the word melanocortin. The FDA April 2026 decision to relax the Scenesse postmarketing cardiac study requirement reflects a regulatory judgment that standard ongoing safety monitoring is sufficient — that is a meaningfully different signal from the compound clinical story than what the viral self-injection posts from this week communicate. The Melanotan-II viral moment in June 2026 is not about afamelanotide. But it should prompt readers curious about melanocortin biology to ask what an actual clinical program for a melanocortin drug looks like — and what the sixteen-year distance between the two represents in terms of evidence, oversight, and understood risk.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.